Roche launched the cobas Hepatitis D Virus (HDV) test, its first fully automated solution to detect and quantify HDV RNA, running on the cobas 5800/6800/8800 platforms. The assay is now available in CE-mark accepting countries, which modestly strengthens Roche’s diagnostics offering but is unlikely to move markets materially in the near term.
Roche launched the cobas Hepatitis D Virus (HDV) test, its first fully automated solution to detect and quantify HDV RNA, running on the cobas 5800/6800/8800 platforms. The assay is now available in CE-mark accepting countries, which modestly strengthens Roche’s diagnostics offering but is unlikely to move markets materially in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
